Leerink Partnrs upgraded shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) to a strong-buy rating in a report released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.46) EPS and FY2026 earnings at ($1.92) EPS.
A number of other research firms have also recently commented on ORKA. Leerink Partners began coverage on shares of Oruka Therapeutics in a report on Tuesday. They issued an outperform rating and a $44.00 target price for the company. Wedbush initiated coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They issued an outperform rating and a $40.00 price objective for the company. Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an outperform rating and a $41.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a buy rating and a $40.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued a buy rating for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $41.25.
Check Out Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Trading Up 0.7 %
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- High Dividend REITs: Are They an Ideal Way to Diversify?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Using the MarketBeat Stock Split Calculator
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.